Ceplene Currently Approved in Europe and IsraelREMAIN(TM) to be a pivotal study for US approval NEW YORK, Feb. 17, 2017 /PRNewswire/ — Immune Pharmaceuticals Inc. (Nasdaq: IMNP), will announce on ...
NEW YORK, Jan. 23, 2017 /PRNewswire/ — Immune Pharmaceuticals Inc. (NASDAQ: IMNP), “Immune”, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of immuno-inflammatory diseases and cancers, announced today ...
RnRMarketResearch adds Chronic Obstructive Pulmonary Disease Market research to its database. PUNE, India, May 18, 2016 /PRNewswire-iReach/ — Chronic Obstructive Pulmonary Disease (COPD) Pipeline Market Companies Involved in Therapeutics Development ...
NEW YORK, May 16, 2016 /PRNewswire/ — Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (“Immune” or the “Company”) announced financial results for the first quarter ended March 31, 2016. Business and Research ...
NEW YORK, March 30, 2016 /PRNewswire/ — Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (“Immune” or the “Company”) announced financial results for the fourth quarter and full year ended December 31, 2015. ...
Re-distribution of cytotoxic T-Cell Subsets During Therapy with Ceplene Predicts Overall Survival in Patients with Acute Myeloid Leukemia NEW YORK, March 17, 2016 /PRNewswire/ — Immune Oncology Pharmaceuticals, a clinical-stage ...
